Brief: Timber Pharmaceuticals Announces Last Patient Last Visit In Phase 2B Control Study Evaluating Tmb-001 In Moderate To Severe Congenital Ichthyosis

Trex Wind-Down

24/08/2021 15:57

Aug 24 (Reuters) - Timber Pharmaceuticals Inc  TMBR.A :
    * TIMBER PHARMACEUTICALS ANNOUNCES LAST PATIENT LAST VISIT
IN
PHASE 2B CONTROL STUDY EVALUATING TMB-001 IN MODERATE TO SEVERE
CONGENITAL ICHTHYOSIS
    * TIMBER PHARMACEUTICALS INC - TOPLINE RESULTS  FROM PHASE
2B
CONTROL STUDY EVALUATING TMB-001 EXPECTED TO BE ANNOUNCED IN Q4
OF 2021
    * TIMBER PHARMACEUTICALS INC - COMPANY PREPARING FOR AN
END-OF-PHASE 2 MEETING WITH FDA

Source text for Eikon:  ID:nGNX6BstCh 
Further company coverage:  TMBR.A 

 ((reuters.briefs@thomsonreuters.com;))